Long-term life after advanced GIST on targeted drug therapy
Part of Cancer, Digestive system clinical trials.
This study follows people who have been taking targeted cancer drugs (called TKIs) for advanced GIST for at least 2 years to understand how these long-term treatments affect quality of life, side effects, and daily living. Researchers want to learn what challenges patients face and how to better support them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have advanced or metastatic GIST confirmed by a tissue biopsy
- You have been taking a TKI drug (like sunitinib, regorafenib, avapritinib, or ripretinib) for at least 2 years and are still taking it (brief breaks of up to 3 months are okay)
- You are able to read and complete questionnaires about your health and life
- You are healthy enough to participate and can give informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at why some GIST tumors stop responding to standard treatments. It uses special imaging and genetic testing of tumor tissue to find resistance patterns, which may guide future treatment choices.
This trial studies people with advanced or metastatic gastrointestinal stromal tumor (GIST) who have been on the drug imatinib for 10 years with stable, non-growing disease. The goal is to see how effective it is to keep imatinib going after this long period.
This study uses a blood test (ctDNA) to look for specific tumor DNA changes, then guides treatment with sunitinib or regorafenib in people with GIST that has spread or cannot be removed by surgery. It aims to see whether this ctDNA-guided approach improves outcomes compared with standard decision-making.
This study looks at taking imatinib (a targeted anti-cancer pill) for 5 years after your GIST tumor has been fully removed. It is meant to lower the chance that GIST comes back in people considered “high risk.”
This study tests a new pill called velzatinib for people with GIST that has spread or can't be removed by surgery, after other treatments have stopped working. It may help shrink the tumor or slow its growth.
This trial tests whether adding a new drug called CGT9486 to sunitinib (a standard cancer drug) works better than sunitinib alone for gastrointestinal stromal tumors (GISTs) that have grown or spread. You may qualify if your GIST stopped responding to or caused problems with imatinib, an earlier treatment.
Hear when a new Gastrointenstinal Stromal Tumor (GIST) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.